BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M. |
| Abstract Title: | BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.138 |
| Language: | English |
| ACCESSION: | WOS:000459277302112 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.138 |
| Notes: | Meeting Abstract: 929TiP -- Appears on page viii331 of the abstract book -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
